TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00406978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide will be administered orally at the initial dose of 50 mg/day p.o. once daily, with increment of 50 mg after a month to acceptable tolerance (maximum 100 mg), continuously for the entire 6 courses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: Lev - 1 Def = 10 mg/Kg (max 0.6 g) on days 1-4, followed by 1.2 g (400 mg every 8 hours) p.o. through day 35 Lev - 1 Def = 1.2 g p.o (400 mg every 8 hours) on days 1-4, followed by 1.2 g (400 mg every 8 hours) p.o. through day 35 Level + 1 Def = 17 mg/Kg (max 1.2 g) on days 1-4, followed by 1.6 g p.o. (400 mg every 6 hours) through day 35 Lev + 1 Def = 2.4 g p.o. (400 mg every 4 hours) on days 1-4, followed by 1.6 g p.o. (400 mg every 6 hours) through day 35 Lev + 2 Def = 34 mg/Kg (max 2.4 g) as a i.v. injection on days 1-4, followed by 3.2 g p.o. (800 mg every 6 hours) through day 35 Lev + 2 Def = 4.8 g p.o. (800 mg every 4 hours) on days 1-4, followed by 3.2 g p.o. (800 mg every 6 hours) through day 35 Lev + 3 Def = 51mg/Kg (max 3.6 g) as a i.v. injection on days 1-4, followed by 4.8 g p.o. (1200 mg every 6 hours) through day 35 Lev + 3 Def = 7.2 g p.o.(1200 mg every 4 hours ) on days 1-4, followed by 4.8 g p.o. (1200 mg every 6 hours) given p.o. through day 35
Study: NCT03650933

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CHOP
Description: 6 cycles(each cycle is 3 weeks)
Study: NCT04613908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuro muscular electro stimulation
Description: We used a commercial equipment of electro stimulation with a pulse width of 300 micro seconds, a frequency of 50 Hz, with symmetrical balanced biphasic rectangular wave and with an intensity of up to 80 milliampere.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Mobilization protocol
Description: The protocol consisted in applying a specific treatment based on different levels of treatment to each subject. Admission to them was carried out according to the maximum capacity of each subject, the conditions of each level being the following:~* Level 1: MRC (shoulder) \<3 + MRC \<3 (hip).~* Level 2: MRC (shoulder) ≥ 3 + MRC (hip) \<3.~* Level 3: MRC (shoulder) ≥ 3 + MRC (hip) ≥ 3 + sitting on the edge of the bed without assistance (minimum 15 minutes).~* Level 4: Standing without assistance and walking with or without assistance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care or usual rehabilitation
Description: routine, non-protocolized rehabilitation treatment performed by the physiotherapist assigned to intensive care
Study: NCT03396029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individually tailored lifestyle feedback
Description: The written, standardized individually tailored lifestyle feedback includes feedback on consumption of fruit, berries and vegetables and alcohol, physical activity, smoking and body mass index.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard leaflet
Description: The leaflet is The Norwegian Cancer Society's one-page information brochure on healthy lifestyle behaviours for low cancer risk, including non-smoking, healthy body weight, physical activity, diet, moderate alcohol consumption, moderate sun exposure etc.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard leaflet
Description: The leaflet is The Norwegian Cancer Society's one-page information brochure on healthy lifestyle behaviours for low cancer risk, including non-smoking, healthy body weight, physical activity, diet, moderate alcohol consumption, moderate sun exposure etc.
Study: NCT01649232

Intervention type: DEVICE
Intervention: Active tDCS
Description: tDCS applied to left dorsolateral prefrontal scalp area through a saline-soaked pair of surface sponge electrodes (35 cm2). The anode electrode was placed over F3 (based on the 10-20 International EEG System) of each subject. The cathode was placed over the contralateral mastoid area. A constant current of 1.1 mA was applied for 25 min/day (administered for 12 alternated days).
Study: NCT00813813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intradiscal rhGDF-5
Description: The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
Study: NCT02292017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embolization of intracranial aneurysm
Description: Cerebral angiogram will be performed, target aneurysm measurements are performed including dome height, width, and depth as well as the neck length. Aneurysm volume will be calculated. During the embolization, framing, filling, and finishing should be done with Target Coils. In the event of aneurysms with a wide neck a Neuroform Stent may be used to ensure the best clinical and angiographic outcome. Immediate post procedure angiography is performed using the same pre-treatment views to assess results and complications.
Study: NCT04984707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KX0826
Description: AR antagonist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of KX-826
Study: NCT01055730

Intervention type: OTHER
Intervention: Pulmonary rehabilitation
Description: Structured education and supervised exercise program, lasting between 6 and 9 weeks.
Study: NCT04699955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deviance Regulation Theory
Description: In the negative message condition, participants received information on the negative aspects of individuals that did not used protective strategies and were encouraged to report why these individuals were viewed so much more negatively. In the positive message condition, participants received information on the positive aspects of individuals that used protective strategies and were encouraged to report why these individuals were viewed so much more positively.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deviance Regulation Theory
Description: In the negative message condition, participants received information on the negative aspects of individuals that did not used protective strategies and were encouraged to report why these individuals were viewed so much more negatively. In the positive message condition, participants received information on the positive aspects of individuals that used protective strategies and were encouraged to report why these individuals were viewed so much more positively.
Study: NCT02331602

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Patients are assigned to receive rivaroxaban 15mg once daily for 12 months. Patients with creatinine clearance 30-49 mL/min receive rivaroxaban 10mg once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran
Description: Patients are assigned to receive dabigatran 150mg twice daily for 12 months. Patients at a high risk of bleeding receive dabigatran 110mg twice daily.
Study: NCT03197012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y-DOTA-TOC
Description: Starting 30 minutes prior to the administration of 90Y-DOTA-TOC, amino acid solution will be administered via IV, and will continue through the PRRT procedure. An angiographic catheter will be inserted under fluoroscopic guidance to the appropriate location in the hepatic artery. 90Y-DOTA-TOC will be administered via the hepatic arterial catheter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y-DOTA-TOC
Description: Starting 30 minutes prior to the administration of 90Y-DOTA-TOC, amino acid solution will be administered via IV, and will continue through the PRRT procedure. An angiographic catheter will be inserted under fluoroscopic guidance to the appropriate location in the hepatic artery. 90Y-DOTA-TOC will be administered via the hepatic arterial catheter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-TOC
Description: In the sub-study, 10 patients will receive 68Ga-DOTA-TOC concurrent with the 90Y-DOTA-TOC dose and 90 minutes after treatment, these patients will be imaged using a PET/CT. The following day, patients enrolled in the sub-study will undergo a PET/MRI.
Study: NCT01956422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure(CPAP)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venturi Mask FiO2 40%
Study: NCT01176721

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: t-VNS verum
Description: Active stimulation of the left auricle by t-VNS

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: t-VNS placebo
Description: Sham stimulation of the left auricle with the t-VNS device
Study: NCT03582774

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-labeled PSMA-11
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT02583425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-11 Injection
Study: NCT01053195

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Non-diabetic high-risk subjects enrolled will be eligible for individual and/or group lifestyle counseling. The intervals of the counseling sessions depend on the glucose levels of the high-risk individuals, every three months for those having prediabetes and every six months for those with normal glucose levels but high risk score.
Study: NCT00687999

Intervention type: DRUG
Group type: OTHER
Intervention: pegylated interferon alpha and ribavirin
Description: standard pegylated interferon alpha and ribavirin
Study: NCT04088721

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AD17002
Description: LTh(αK) as immunomodulator

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AD17002
Description: LTh(αK) as immunomodulator

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AD17002
Description: LTh(αK) as immunomodulator

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Formulation Buffer
Description: Formulation buffer
Study: NCT03440749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: luminous stimuli
Description: The child is placed in front of a screen on which 4 luminous stimuli are presented on a horizontal plane. Four buzzers are placed in front of him, each buzzer corresponds to the position of a stimulus. Child had to push the buzzer corresponding to the place of the luminous stimuli.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: luminous stimuli
Description: The child is placed in front of a screen on which 4 luminous stimuli are presented on a horizontal plane. Four buzzers are placed in front of him, each buzzer corresponds to the position of a stimulus. Child had to push the buzzer corresponding to the place of the luminous stimuli.
Study: NCT01977300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate
Description: serum level of 50 to 125 ug/L

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: serum level of 50 to 125 ug/L

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valproate
Description: serum level of 50 to 125 ug/L

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: serum levels of 0.6 to 1.2 mmol/L

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: serum levels of 0.6 to 1.2 mmol/L

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lithium
Description: serum levels of 0.6 to 1.2 mmol/L

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: 1 to 6 mg/day
Study: NCT03738813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gloreha Aria
Description: Device offers specific programs that help patients to move arm, wrist and fingers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Conventional occupational therapy
Study: NCT04447001

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai-chi prime (TCP)
Description: TCP is a 6-week twice-weekly simplified tai chi class of 1.5 hr per session with two components: (a) Tai-chi fundamental Adapted Program, and (b) home practice coaching.
Study: NCT03159871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stratafix suture
Description: Stratafix barbed sutures during C-Sections.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl suture
Description: Standart Vicryl suture during C- Sections.
Study: NCT00712543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lactulose (Kristalose®)
Description: Crystals to be dissolved in water and taken as prescribed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liquid lactulose
Description: Liquid to be taken as prescribed.
Study: NCT03436693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Canagliflozin 100mg orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally once daily
Study: NCT03406559

Intervention type: OTHER
Group type: OTHER
Intervention: orthodontic treatment
Description: fixed orthodontic treatment in adolescent males initially treated with removable functional appliances for skeletal class II, Angle's class II division 2 malocclusion,
Study: NCT03403829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine maintenance chemotherapy

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: standard chemoradiotherapy
Description: standard chemoradiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: standard chemoradiotherapy
Description: standard chemoradiotherapy
Study: NCT03650933

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R-CHOP
Description: 6 cycles(each cycle is 3 weeks)
Study: NCT02659202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision Spinal Cord Stimulator System
Description: The precision system will consist of a pulse generator that will not be implanted, temporary percutaneous leads, surgical paddle leads and lead extensions, each packaged as a separate kit.
Study: NCT03836781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Ketorolac 3% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe

Intervention type: DRUG
Group type: OTHER
Intervention: Chlorhexidine 2%
Description: Chlorhexidine 2% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
Study: NCT03662919

Intervention type: DRUG
Intervention: Infliximab
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Intervention: Adalimumab
Description: Administered as specified in the treatment arm.
Study: NCT04275687

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thoracic irradiation
Description: For peripherally located recurrent tumors, stereotactic body radiation therapy is used at 5000-6000 cGy in 10 fractions.~For centrally located recurrent tumors, adaptive hypofractionated radiation is used: Patients are irradiated at 3000-4000cGy in 6-10 daily fractions in the first course. After a four-week interval, patients who have non-progressive disease and an adequate pulmonary function undergo adaptive re-planning, and are irradiated at 2400-3500cGy in 4\~7 daily fractions as a boost.
Study: NCT01977300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: 1 to 6 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: 5 to 25 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 5 to 25 mg/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: manufactured to mimic risperidone and olanzapine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: manufactured to mimic risperidone and olanzapine
Study: NCT04419402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-PSMA
Description: Patients will be given 7.5 GBq of Lu-PSMA in 4 doses. Dose 1 and 2 on Days 15 and 57. Doses 3 and 4 (Days 113 and 169) will be given following result of 68Ga-PSMA PET/CT at Day 92.~Treatment administered every 6 weeks, x 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: 160 mg (four 40 mg capsules) daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg (four 40 mg capsules) daily.
Study: NCT01566331

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baby-guardTM
Description: Baby-guardTM system, through its ergonomic, three chamber, inflatable abdominal belt, engineered after studies of biomechanics and biophysics, that follows obstetric semiotics, that applies fundal pressure during the second stage of labor in the direction of the pelvic outlet, may be of maternal and fetus aid for a safe natural childbirth for their better outcomes
Study: NCT00863655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus was formulated as tablets of 5-mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane 25 mg orally daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Exemestane 25 mg orally daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus Placebo
Description: Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
Study: NCT00644202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling Sessions
Description: Counseling Sessions at each study visit around diet and physical activity from a registered dietician

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specialized Website
Description: Specialized website that allows participants to track their eating and physical activity patterns, learn new weight management skills, interact with the dietician, and receive support from other participants

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling Calls
Description: 5 telephone calls with a health counselor, lasting 15-20 minutes each.
Study: NCT04351503

Intervention type: OTHER
Intervention: Study A
Description: Study A: collection of data of clinical outcomes and features of SARS-CoV-2 infection. Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analyzed. For this study part, only patients with a visit at the University Hospital Basel will be included in order to access patient charts.

Intervention type: OTHER
Intervention: Study A
Description: Study A: collection of data of clinical outcomes and features of SARS-CoV-2 infection. Demographical, clinical, microbiological, laboratory, epidemiological and hospital-associated data will be analyzed. For this study part, only patients with a visit at the University Hospital Basel will be included in order to access patient charts.

Intervention type: OTHER
Intervention: Study B
Description: Study B: collection of epidemiological surveillance data to describe the epidemiology of the SARS-CoV-2 outbreak. The epidemic transmission of Influenza viruses in the City of Basel serves as an important reference to identify similarities and differences to the pandemic SARS-CoV-2 situation. In addition data collected during the Influenza projects - in particular data on statistical blocks of the city, e.g. population density, income and living space will be re-used. Already collected and stored samples such as serum and respiratory material (leftover material) will be (re-) used.
Study: NCT04275687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy
Description: For centrally located recurrent tumors, concurrent chemotherapy consists of weekly docetaxel and nedaplatin.
Study: NCT05180578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goat milk diet
Description: Elimination of cow milk from diet . Goat milk containing diet.
Study: NCT04351503

Intervention type: OTHER
Intervention: Study C
Description: Study C: data collection for viral evolution. Respiratory materials and matching blood and tissue materials will be used to perform whole genome sequencing to study pathogen evolution between hosts as well as in-host evolution. No additional material will be collected.

Intervention type: OTHER
Intervention: Study D
Description: Study D: collection of safety and efficacy data of different treatment modalities. Currently the following treatments are considered as part of the treatment:~1. Lopinavir/Ritonavir~2. Hydroxychloroquine~3. Tocilizumab~4. Eculizumab~5. Ruxolitinib~6. Remdesivir~7. Treatment with convalescent plasma blood count, blood chemistry and pulmonary function test (collected on a routine basis during hospitalization and in the outpatient setting).
Study: NCT04479436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab Deruxtecan
Description: U3-1402 will be dosed at 5.6 mg/kg as an intravenous (IV) infusion administered on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab Deruxtecan
Description: U3-1402 will be dosed at 5.6 mg/kg as an intravenous (IV) infusion administered on Day 1 of each 21-day cycle.